Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection

J Infect Dis. 2015 Sep 1;212(5):779-83. doi: 10.1093/infdis/jiv108. Epub 2015 Feb 26.


We evaluated immune responses following bivalent oral cholera vaccination (Shanchol [Shantha Biotechnics]; BivWC) in a cohort of 25 human immunodeficiency virus (HIV)-infected adults in Haiti. Compared with adults without HIV infection, vaccination in HIV-infected individuals resulted in lower vibriocidal responses against Vibrio cholerae O1, and there was a positive relationship between the CD4(+) T-cell count and vibriocidal responses following vaccination. Nevertheless, seroconversion occurred at a rate of 65% against the Ogawa serotype and 74% against the Inaba serotype in adults with HIV infection. These results suggest that the vaccine retains substantial immunogenicity in adults with HIV infection and may benefit this population by protecting against cholera.

Keywords: Cholera vaccine; HIV; Shanchol (BivWC); immunogenicity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Blood Bactericidal Activity
  • CD4 Lymphocyte Count
  • Cholera / prevention & control*
  • Cholera Vaccines / administration & dosage
  • Cholera Vaccines / immunology*
  • Cohort Studies
  • Female
  • HIV Infections / complications
  • HIV Infections / immunology*
  • Haiti
  • Humans
  • Immunoglobulin A / blood
  • Male
  • Microbial Viability
  • Middle Aged


  • Cholera Vaccines
  • Immunoglobulin A
  • shanchol